Replimune Group, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
REPL Nasdaq 2836 www.replimune.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Replimune Group, Inc.

Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma - Oct 1st, 2026 2:01 pm
Replimune to Present at the Cantor Global Healthcare Conference 2026 - Sep 3rd, 2026 6:00 am
Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today? - Aug 26th, 2026 9:13 pm
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 19th, 2026 2:01 pm
Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update - Aug 14th, 2026 6:00 am
Replimune Group (REPL) Wins FDA Approval For Advanced Melanoma Treatment - Aug 13th, 2026 4:14 pm
Why Did ABCL, REPL, ABNB Stocks Hit 52-Week Highs Today? - Aug 10th, 2026 8:31 pm
REPL Stock Hits Near 18-Month High On Pricing Of $150M Offering – But, Retail Sees Share Price ‘Unwinding Over Time’ - Aug 10th, 2026 10:21 am
This Biotech’s Drug Could Treat Hot Flashes. The Stock Is Up 34% on Good News. - Aug 10th, 2026 10:20 am
Replimune’s First Commercial Drug Arrives—With A 2027 Cash Cliff And 2030 Finish Line - Aug 7th, 2026 6:31 pm
Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock Is Tumbling. - Aug 7th, 2026 1:33 pm
Why Did IOVA, REPL, ROKU Stocks Surge To 52-Week Highs Today? - Aug 6th, 2026 8:40 pm
REPL Stock Slumps 11% After-Hours — What’s Driving The Selloff? - Aug 6th, 2026 3:37 pm
Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen - Aug 6th, 2026 2:00 pm
Walmart downgraded, Palantir upgraded: Wall Street's top analyst calls - Aug 4th, 2026 7:37 am
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Apple, CoreWeave, eBay, Exxon Mobil, Intuit, Nebius Group, Palantir Technologies, SK hynix, and More - Aug 4th, 2026 6:11 am
Replimune’s Melanoma FDA Decision Pending: This Analyst Sees 40% Upside, ‘High Conviction’ For Approval - Aug 4th, 2026 4:44 am